Status:
UNKNOWN
Safety and Efficacy Study of Ex Vivo Immunotherapy for Treatment of Aplastic Anemia
Lead Sponsor:
Shenzhen Zhongxing Yangfan Biotech Co. Ltd.
Collaborating Sponsors:
The 12th Guangzhou Municipal Hospital
Liu Hua Qiao Hospital
Conditions:
Anemia, Aplastic
Eligibility:
All Genders
10-80 years
Phase:
PHASE1
PHASE2
Brief Summary
Our hypothesis is that ex vivo activated immune cells would produce multiple known and unknown potent hematopoietic cytokines, working in concert, these cytokines help stem cell growth and differentia...
Detailed Description
Patients will be required to stay in our hospitals to receive the immunotherapy. Allogeneic peripheral blood mononuclear cells from healthy donors and the autologous peripheral mononuclear cells will ...
Eligibility Criteria
Inclusion
- Clinical Diagnosis of Idiopathic Aplastic Anemia
- Not Eligible for Bone Marrow Transplantation
- Not Responsive to Conventional Immunosuppressive Therapy
Exclusion
- Leukemia or MDS or PNH or Fanconi's Disease
- pregnancy
- Allergic to Blood Product
- Severe Hypertension or Heart Disease
- Liver or Kidney Disease
Key Trial Info
Start Date :
November 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2009
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00399971
Start Date
November 1 2002
End Date
December 1 2009
Last Update
November 11 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Hematology, Liu Hua Qiao Hospital
Guangzhou, Guangdong, China, 50010